How much funding has Ollin Biosciences raised?

Ollin Biosciences has raised $430.0M in total funding, most recently a Series B round.

Who are Ollin Biosciences's investors?

Ollin Biosciences's investors include ARCH Venture Partners, TCGX, Andreessen Horowitz, Mubadala Investment Company, T. Rowe Price, Canada Pension Plan Investment Board.

When was Ollin Biosciences founded?

Ollin Biosciences was founded in 2023.

Where is Ollin Biosciences headquartered?

Ollin Biosciences is headquartered in Austin, Texas, United States.

What industry is Ollin Biosciences in?

Ollin Biosciences operates in Biotech, Healthcare.

How many employees does Ollin Biosciences have?

Ollin Biosciences has 11-50 employees.

Ollin Biosciences

Redefining What's Possible in Ophthalmology

Austin, United States · Founded 2023 · $430.0M raised

Biotech

Healthcare

Headquarters: Austin, Texas
Employees: 11–50
Founded: 2023
Business Model: B2B

Website: ollin.bio
Total Funding: $430.0M
Last Round: $330.0M Series BJun 2026
Rounds: 2

About

Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. Founded in 2023 and based in Austin, Texas, the company is advancing a pipeline of bispecific antibody programs including OLN324, a VEGF/Ang2 bispecific antibody in Phase 1b trials for wet AMD and diabetic macular edema, and OLN102 for thyroid eye disease.

Summary

Ollin Biosciences is a Biotech company based in Austin, United States, founded in 2023. It has raised $430.0M in total across 2 rounds, most recently a $330.0M Series B round in Jun 2026. Investors include ARCH Venture Partners, TCGX and Andreessen Horowitz.

LinkedIn X (Twitter)